{
  "pmcid": "12492990",
  "sha256": "d84fa9d9c1ba45538c13b40d2c25232cfeac50990ee2379c721c6523ea47527c",
  "timestamp_utc": "2025-11-09T23:41:47.753802+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.678703703703707,
    "reading_ease": 6.699166666666713,
    "word_count": 270
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Neuromuscular Blocking Agents in Anesthesia"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were recruited from diverse age groups, with eligibility criteria including age-specific physiological characteristics. The study was conducted in a clinical anesthesiology setting."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved administering NMBAs with adjustments based on age-related pharmacokinetics, compared to standard dosing regimens."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to clarify dosage differences and their physiological bases."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of residual muscle blockade, measured over a 24-hour period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant reduction in residual blockade (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group, with mild gastrointestinal side-effects being the most common."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the Anesthesiology Research Foundation."
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}